Sinopharm expanded globally across Belt and Road nations, boosting vaccine partnerships, local production, and China’s pharmaceutical influence worldwide.
Sinopharm Group, a prominent Chinese centrally-owned enterprise, has significantly amplified its global operations in recent years, now extending its product reach to over 70 countries and regions. A key focus of this international expansion has been countries involved in the Belt and Road Initiative (BRI), where Sinopharm is actively developing new markets.
A major driver of this international push is Sinopharm's vaccine business. The company is vigorously pursuing overseas production capacity collaborations and expediting product approvals in crucial regions worldwide. Liu Tun, deputy director of Sinopharm's public affairs department, highlighted the establishment of localization production agreements or intentions with partners in several nations, including Indonesia, Myanmar, Brazil, Egypt, Morocco, Ghana, Saudi Arabia, and Hungary. These agreements encompass a range of vital vaccines, such as those for rotavirus, hepatitis B, influenza, and rabies. Notably, the hepatitis B vaccine is already being locally packaged in Myanmar and has received market approval from the country's drug regulatory authority.
Luo Jian, deputy general manager of Sinopharm's Shanghai Institute of Biological Products Co Ltd, further elaborated on the company's engagement with BRI countries and regions. Discussions are currently underway regarding vaccine products for measles, mumps, rubella, and BCG, which is used to prevent tuberculosis in children.
Founded in 1987, Sinopharm holds the distinction of being China's sole centrally-owned enterprise dedicated to life and health. Its overarching objectives include elevating national healthcare standards and bolstering the international competitiveness of China's pharmaceutical industry. The group's extensive operations now span Europe, Asia, Africa, the Americas, and Oceania, fostering partnerships in over 190 countries, regions, and international organizations. Beyond vaccines, Sinopharm has also seen substantial growth in the export of traditional Chinese medicine (TCM) to BRI countries and regions, establishing 2,000 sales terminals and 1,000 TCM clinics overseas.
This aggressive internationalization by Sinopharm carries significant geopolitical and economic implications. Economically, it signifies China's growing influence in the global pharmaceutical market, potentially increasing its share in vaccine and traditional medicine supply chains, particularly in developing nations. For the recipient countries, these partnerships could lead to improved access to essential medicines and vaccines, and potentially foster local pharmaceutical manufacturing capabilities through technology transfer and localization agreements. Geopolitically, Sinopharm's expansion, especially within the BRI framework, aligns with China's broader strategy of strengthening economic and political ties with participating nations, extending its soft power through healthcare initiatives. The focus on vaccine production and distribution also positions China as a key player in global health security, particularly in a post-pandemic world.
